Marker Therapeutics to Present MT-601 Data for Relapsed Non-Hodgkin and Hodgkin Lymphoma at 67th ASH Annual Meeting
Study Overview: The Phase 1 APOLLO study is investigating MT-601, a Multi-Antigen Recognizing (MAR)-T cell therapy, in patients with relapsed B cell lymphomas, showing promising preliminary efficacy data with an objective response rate of 66% in Non-Hodgkin lymphoma and 78% in Hodgkin lymphoma.
Safety Profile: MT-601 demonstrated a robust safety profile with no dose limiting toxicities or immune-effector cell associated neurotoxicity syndrome reported, and only two participants experienced mild cytokine release syndrome.
Upcoming Presentations: Data from the APOLLO study will be presented in two posters at the 67th American Society of Hematology Annual Meeting from December 6-9, 2025, highlighting the safety and efficacy of MT-601 in relapsed or refractory lymphomas.
Company Background: Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company focused on developing next-generation T cell-based therapies for hematological malignancies and solid tumors, with a commitment to operational excellence and patient outcome improvement.
Get Free Real-Time Notifications for Any Stock
Analyst Views on MRKR
About MRKR
About the author
Biotech Surge Post-Market: Inspira, MediciNova, and DiaMedica Therapeutics Among Top Performers
Biotech Stocks Performance: Several small-cap biotech and healthcare companies saw notable gains in after-hours trading, driven by recent corporate updates and clinical milestones.
Inspira Technologies Update: Inspira Technologies Oxy B.H.N. Ltd. rose 5.88% following a recent agreement for a registered direct offering and a Standby Equity Purchase Agreement, despite no new news on the day.
MediciNova's Clinical Trial Success: MediciNova, Inc. advanced 4.83% after successfully completing patient enrollment in its Phase 2 OXTOX study, which evaluates MN-166 for preventing chemotherapy-induced peripheral neuropathy.
DiaMedica's FDA Meeting: DiaMedica Therapeutics Inc. gained 2.89% after a productive pre-IND meeting with the FDA regarding its study of DM199 in preeclampsia, with an additional non-clinical study requested.
Merakris Presents MTX-001 Biologic Drug at Innovations in Wound Healing Symposium
- Scientific Exchange Platform: Merakris' Chief Scientific Officer, Dr. Roger Ilagan, has been invited to present at the Innovations in Wound Healing Symposium from December 11-14, 2025, sharing updates on MTX-001 to advance scientific dialogue in biologic drug development.
- Clinical Trial Progress: MTX-001, a first-in-class injectable biologic derived from cell-free amniotic fluid, is currently undergoing a multicenter Phase 2 trial (NCT04647240), with Part 1 completed and published in the International Wound Journal in March 2025, demonstrating promising safety and tolerability.
- Expanded Access Program: The therapy is available through an Expanded Access Program (EAP) for patients with cutaneous wounds, such as diabetic foot ulcers and pressure sores, reflecting Merakris' responsiveness to patient needs and market adaptability.
- Industry Leadership: Merakris is focused on developing biologically derived products to improve wound healing, showcasing its innovative leadership in regenerative medicine through advanced biologic manufacturing capabilities and a robust research pipeline.
